Copyright
©The Author(s) 2023.
World J Gastrointest Surg. May 27, 2023; 15(5): 871-881
Published online May 27, 2023. doi: 10.4240/wjgs.v15.i5.871
Published online May 27, 2023. doi: 10.4240/wjgs.v15.i5.871
Figure 5 Plasma incretin levels.
A: Plasma levels of gastric inhibitory peptide; B: Plasma levels of glucagon-like polypeptide-1. Plasma levels of gastric inhibitory peptide and glucagon-like peptide-1 were measured by ELISA. aP < 0.05 compared with the TJ-43(-) group by ANOVA with Bonferroni’s post-hoc test. TJ-43: Rikkunshito; TJ-43(-): Patients without TJ-43 treatment; TJ-43(+): Patients with TJ-43 treatment; GIP: Gastric inhibitory peptide; active GLP-1: Glucagon-like polypeptide-1; POD: Postoperative day.
- Citation: Kono H, Hosomura N, Amemiya H, Shoda K, Furuya S, Akaike H, Kawaguchi Y, Kawaida H, Ichikawa D. Rikkunshito increases appetite by enhancing gastrointestinal and incretin hormone levels in patients who underwent pylorus-preserving pancreaticoduodenectomy: A retrospective study. World J Gastrointest Surg 2023; 15(5): 871-881
- URL: https://www.wjgnet.com/1948-9366/full/v15/i5/871.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v15.i5.871